Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 9:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 5,060 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Major Depressive Disorder, Alcohol Abuse, Alcohol Dependence
Interventions: acamprosate, escitalopram, Medical management, Placebo; Drug · Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 64 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Head and Neck Cancer
Interventions: Fenretinide (4-HPR), SCH66336; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Opioid Use Disorder
Interventions: Placebo, Cannabidiol (CBD) 200mg, Cannabidiol (CBD) 400mg; Drug
Lead sponsor: Yasmin Hurd; Other
Eligibility: 18 Years to 65 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Ulcerative Colitis, Ileal Pouch
Interventions: Aquamin; Drug
Lead sponsor: Muhammad N Aslam, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Overweight, Diabetes, PreDiabetes, Obesity
Interventions: Gelesis200, Placebo; Device
Lead sponsor: Gelesis, Inc.; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 12
States / cities: Birmingham, Alabama • Bradenton, Florida • Miami, Florida + 9 more

Conditions: Diabetic Retinopathy
Interventions: doxycycline monohydrate, Placebo; Drug
Lead sponsor: Thomas Gardner; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Angina Pectoris
Interventions: T89; Drug
Lead sponsor: Tasly Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 15
States / cities: Tucson, Arizona • Beverly Hills, California • Corona, California + 11 more

Conditions: Healthy
Interventions: Cefadroxil 500 mg Capsules, DURICEF® capsules 500 mg; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Mild Cognitive Impairment
Interventions: Curcumin, aerobic yoga, non aerobic yoga, Placebo; Drug · Behavioral · Dietary Supplement
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years to 90 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: West Los Angeles, California

Conditions: Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD)
Interventions: Cariprazine Flexible Dose; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 40
States / cities: Dothan, Alabama • Bentonville, Arkansas • Anaheim, California + 31 more

Conditions: Mild Cognitive Impairment (MCI)
Interventions: Gamma- Glutamylcysteine, Gamma- Glutamylcusteine; Drug
Lead sponsor: Pravat Mandal; Other
Eligibility: 55 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hepatic Impairment
Interventions: Omaveloxolone 50 mg capsules; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Tustin, California • Miami, Florida • Orlando, Florida

Conditions: BPH (Benign Prostatic Hyperplasia), Lower Urinary Track Symptoms
Interventions: raloxifene, Finasteride; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Neoplasm, Colon Neoplasm, Pancreatic Neoplasm, Bladder Neoplasm
Interventions: MLN8054; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Weight Loss
Interventions: Advantra Z, Advantra Z + Naringin + Hesperiden, Sugar pill; Dietary Supplement · Other
Lead sponsor: Integrative Health Technologies, Inc.; Network
Eligibility: 21 Years and older
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Trichotillomania, Hair Pulling
Interventions: N-Acetylcysteine, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 8 Years to 17 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Peanut Allergy
Interventions: AR101; Biological
Lead sponsor: Aimmune Therapeutics, Inc.; Industry
Eligibility: 4 Years to 55 Years
Enrollment: 388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 47
States / cities: Tucson, Arizona • Little Rock, Arkansas • Mission Viejo, California + 39 more

Conditions: Advanced Cancer
Interventions: Valproic Acid, Bevacizumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Tumor, Cancer, Pain, Malignant Solid Tumor, Unresectable Malignant Neoplasm, Hematologic Malignancy, Multiple Myeloma, Lymphoma, Neoplasm Metastasis
Interventions: Sodium Bicarbonate; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Obstructive Sleep Apnea
Interventions: Placebo oral capsule, Acetazolamide; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney
Interventions: Bardoxolone methyl capsules; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 30
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more

Conditions: Breast Cancer
Interventions: PF-07220060, letrozole, abemaciclib, palbociclib, ribociclib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,035 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 216
States / cities: Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 132 more

Conditions: Cancer
Interventions: Rosuvastatin10 mg tablet, Midazolam 3 mg syrup, Dabrafenib 75 mg capsule; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Cortical Excitability, Psychiatric Disorder
Interventions: L-theanine, Placebo; Drug
Lead sponsor: Butler Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Providence, Rhode Island

Search by objective public record fields.

Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism

4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)

Cannabidiol in the Treatment of Opioid Use Disorder

Aquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal Inflammation

Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects w/o Type 2 Diabetes

Evaluation of Effect of Doxycycline Verses Placebo on Retinal Function and Diabetic Retinopathy

Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina

Cefadroxil 500 mg Capsules Under Fasting Conditions

Curcumin and Yoga Therapy for Those at Risk for Alzheimer's Disease

Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder

Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients

A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function

New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia

A Study of MLN8054 in Patients With Advanced Solid Tumors

A Comparative Effectiveness Study Evaluating the Effects of Thermogenic Supplements on Body Composition

N-Acetylcysteine for Pediatric Trichotillomania

PALISADE Follow-on Study (ARC004)

Valproic Acid and Bevacizumab in Patients With Advanced Cancer

Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain

Acetazolamide on REM OSA

A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam

Effects of L-theanine on Motor Cortex Excitability in Healthy Subjects: A Paired-Pulse TMS Study